Litigation

Recent Posts

Glaxo To Plead Guilty, Will Pay $3 Billion Stemming From Drug Marketing
Posted on 2 Jul 2012 by Tom Moylan

BOSTON - (Mealey's) GlaxoSmithKline LLC (GSK) agreed June 2 to plead guilty and to pay $3 billion to resolve broad-ranging criminal and civil allegations in Massachusetts federal court regarding the promotion of several prescription drugs, failure... Read More

Tags: diabetes drug , Lotronex , Wellbutrin , drugs , GlaxoSmithKline LLC , False Claims Act , United States ex rel. Greg Thorpe v. GlaxoSmithKline PLC , Imitrex , Valtrex , Paxil , antidepressants , United States of America v. GlaxoSmithKline LLC , U.S. Department of Justice , U.S. Food and Drug Administration , Litigation , GSK , Flovent , prescription drugs , Avandia

William A. Ruskin: Comcast May Be A Class Action Game-Changer, But Not In Boston
Posted on 3 Jan 2014 by William A. Ruskin

By William A. Ruskin | In Comcast Corp. v Behrend , 133 S.Ct. 1426 (March 27, 2013) [ enhanced opinion available to lexis.com subscribers ], the Supreme Court held that the lower court erred in failing to consider flaws in plaintiffs' damages model... Read More

Tags: Supreme Court , Wellbutrin , Wal-Mart , Boston , Massachusetts , average price differential , AstraZeneca , In re: Nexium (Esomeprazole) Antitrust Litigation , In re: Rail Freight Fuel , Dr. Meredith Rosenthal , Comcast , Reference Manual On Scientific Evidence , class certification , welfare , William A. Ruskin , generic suppression , damages model , Litigation , Nexium , class actions , GlaxoSmithKline , Rule 23(b)(3) , Sheet Metal Workers Local 1141 Health and Welfare Plan v. GlaxoSmithKline , Evidence , health , Comcast v. Behrend